Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients
Zhen-Chuan Fan,
Ya-Xiong Tao,
Zhen-Chuan Fan
Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
Search for more papers by this authorYa-Xiong Tao
Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
Search for more papers by this authorZhen-Chuan Fan,
Ya-Xiong Tao,
Zhen-Chuan Fan
Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
Search for more papers by this authorYa-Xiong Tao
Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
Search for more papers by this author Ya-Xiong TAO, Ph.D., Department of Anatomy, Physiology and Pharmacology, 212 Greene Hall, College of Veterinary Medicine, Auburn University, Auburn, AL 36849-5519, USA.Tel.: +1 334 844 5396Fax: +1 334 844 5388E-mail: [email protected]
Abstract
As the most common monogenic form of human obesity, about 130 naturally occurring melanocortin-4 receptor (MC4R) gene mutations have been identified. In this study, we reported detailed functional characterization of 10 novel human MC4R (hMC4R) mutants including R7C, C84R, S127L, S136F, W174C, A219V, P230L, F261S, I317V and L325F. Flow cytometry experiments showed that six mutants, including R7C, C84R, S127L, W174C, P230L and F261S, have decreased cell surface expression. The other four mutants are expressed at similar levels as the wild-type hMC4R. Binding assays showed that the mutants have similar binding affinities for the agonist and endogenous antagonist agouti-related protein. Signalling assays showed that S136F is defective in signalling. Multiple mutagenesis showed that S136 of hMC4R is required for the normal function of the receptor. To identify potential therapeutic approaches for patients with intracellularly retained MC4R mutants, we tested the effect of an MC4R inverse agonist, ML00253764, on C84R and W174C. We showed that ML00253764 could function as a pharmacological chaperone rescuing the mutant MC4Rs to the cell surface. The rescued mutants are functional with increased cAMP production in response to agonist stimulation. In conclusion, of 10 mutants we studied, 6 had decreased cell surface expression. Pharmacological chaperone is a potential approach for treating obesity caused by MC4R mutations that result in intracellular retention.
References
- 1 Comuzzie AG, Allison DB. The search for human obesity genes. Science. 1998; 280: 1374–7.
- 2 Montague CT, Farooqi IS, Whitehead JP, et al . Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997; 387: 903–8.
- 3 Clement K, Vaisse C, Lahlou N, et al . A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998; 392: 398–401.
- 4 Jackson RS, Creemers JW, Ohagi S, et al . Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet. 1997; 16: 303–6.
- 5 Krude H, Biebermann H, Luck W, et al . Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998; 19: 155–7.
- 6 Lee YS, Poh LK, Loke KY. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J Clin Endocrinol Metab. 2002; 87: 1423–6.
- 7 Tao YX, Segaloff DL. Functional characterization of melanocortin-3 receptor variants identify a loss-of-function mutation involving an amino acid critical for G protein-coupled receptor activation. J Clin Endocrinol Metab. 2004; 89: 3936–42.
- 8 Vaisse C, Clement K, Guy-Grand B, et al . A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet. 1998; 20: 113–4.
- 9 Yeo GS, Farooqi IS, Aminian S, et al . A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet. 1998; 20: 111–2.
- 10 Holder JL Jr, Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet. 2000; 9: 101–8.
- 11 Huszar D, Lynch CA, Fairchild-Huntress V, et al . Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997; 88: 131–41.
- 12 Ollmann MM, Wilson BD, Yang YK, et al . Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997; 278: 135–8.
- 13 Graham M, Shutter JR, Sarmiento U, et al . Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet. 1997; 17: 273–4.
- 14 Fan W, Boston BA, Kesterson RA, et al . Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997; 385: 165–8.
- 15 Farooqi IS, Keogh JM, Yeo GS, et al . Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003; 348: 1085–95.
- 16 Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005; 8: 571–8.
- 17 Tao YX. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol. 2005; 239: 1–14.
- 18 Gantz I, Fong TM. The melanocortin system. Am J Physiol. 2003; 284: E468–74.
- 19 Smith R, Healy E, Siddiqui S, et al . Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol. 1998; 111: 119–22.
- 20 Tao YX. Inactivating mutations of G protein-coupled receptors and diseases: Structure-function insights and therapeutic implications. Pharmacol Ther. 2006; 111: 949–73.
- 21 Hinney A, Bettecken T, Tarnow P, et al . Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metab. 2006; 91: 1761–9.
- 22 Hainerova I, Larsen LH, Holst B, et al . Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab. 2007; 92: 3689–96.
- 23 Hinney A, Hohmann S, Geller F, et al . Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metab. 2003; 88: 4258–67.
- 24 Rettenbacher E, Tarnow P, Brumm H, et al . A novel non-synonymous mutation in the melanocortin-4 receptor gene (MC4R) in a 2-year-old Austrian girl with extreme obesity. Exp Clin Endocrinol Diabetes. 2007; 115: 7–12.
- 25 Buono P, Pasanisi F, Nardelli C, et al . Six novel mutations in the proopiomelanocortin and melanocortin receptor 4 genes in severely obese adults living in southern Italy. Clin Chem. 2005; 51: 1358–64.
- 26 Larsen LH, Echwald SM, Sorensen TI, et al . Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab. 2005; 90: 219–24.
- 27 Shao XY, Jia WP, Cai SB, et al . Cloning and functional analysis of melanocortin 4 receptor mutation gene F261S. Zhonghua Yi Xue Za Zhi. 2005; 85: 366–9.
- 28 Morello JP, Salahpour A, Laperriere A, et al . Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest. 2000; 105: 887–95.
- 29 Noorwez SM, Kuksa V, Imanishi Y, et al . Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem. 2003; 278: 14442–50.
- 30 Noorwez SM, Malhotra R, McDowell JH, et al . Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J Biol Chem. 2004; 279: 16278–84.
- 31 Janovick JA, Maya-Nunez G, Conn PM. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab. 2002; 87: 3255–62.
- 32 Janovick JA, Goulet M, Bush E, et al . Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther. 2003; 305: 608–14.
- 33 Chaipatikul V, Erickson-Herbrandson LJ, Loh HH, et al . Rescuing the traffic-deficient mutants of rat í-opioid receptors with hydrophobic ligands. Mol Pharmacol. 2003; 64: 32–41.
- 34 Petaja-Repo UE, Hogue M, Bhalla S, et al . Ligands act as pharmacological chaperones and increase the efficiency of ™ opioid receptor maturation. EMBO J. 2002; 21: 1628–37.
- 35 Fan J, Perry SJ, Gao Y, et al . A point mutation in the human melanin concentrating hormone receptor 1 reveals an important domain for cellular trafficking. Mol Endocrinol. 2005; 19: 2579–90.
- 36 Van Craenenbroeck K, Clark SD, Cox MJ, et al . Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis. J Biol Chem. 2005; 280: 19350–7.
- 37 Robert J, Auzan C, Ventura MA, et al . Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone. J Biol Chem. 2005; 280: 42198–206.
- 38 Hawtin SR. Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor. J Biol Chem. 2006; 281: 14604–14.
- 39 Fortin JP, Dziadulewicz EK, Gera L, et al . A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor. Mol Pharmacol. 2006; 69: 1146–57.
- 40 Bernier V, Morello JP, Zarruk A, et al . Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2006; 17: 232–43.
- 41 Vos TJ, Caracoti A, Che JL, et al . Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem. 2004; 47: 1602–4.
- 42 Nicholson JR, Kohler G, Schaerer F, et al . Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther. 2006; 317: 771–7.
- 43 Tao YX, Segaloff DL. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology. 2003; 144: 4544–51.
- 44 Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987; 7: 2745–52.
- 45 Fan ZC, Sartin JL, Tao YX. Molecular cloning and pharmacological characterization of porcine melanocortin-3 receptor. J Endocrinol. 2008; 196: 139–48.
- 46 Wang SX, Fan ZC, Tao YX. Functions of acidic transmembrane residues in human melanocortin-3 receptor binding and activation. Biochem Pharmacol. 2008; 76: 520–30.
- 47 Srinivasan S, Lubrano-Berthelier C, Govaerts C, et al . Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest. 2004; 114: 1158–64.
- 48 Hobbs HH, Russell DW, Brown MS, et al . The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990; 24: 133–70.
- 49 Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993; 73: 1251–4.
- 50 Lubrano-Berthelier C, Durand E, Dubern B, et al . Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet. 2003; 12: 145–53.
- 51 Valli-Jaakola K, Lipsanen-Nyman M, Oksanen L, et al . Identification and characterization of melanocortin-4 receptor gene mutations in morbidly obese Finnish children and adults. J Clin Endocrinol Metab. 2004; 89: 940–5.
- 52 Fang QC, Jia WP, Cai SB, et al . Intracellular retention of human melanocortin-4 receptor: a molecular mechanism underlying early-onset obesity in F261S pedigree of Chinese. Biomed Environ Sci. 2008; 21: 280–5.
- 53 Tan K, Pogozheva ID, Yeo GS, et al . Functional characterization and structural modeling of obesity-associated mutations in the melanocortin 4 receptor. Endocrinology. 2008; 53: 114–25.
- 54 Tao YX. Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanism of activation and therapeutics. Pharmacol Ther. 2008; 120: 129–48.
- 55 Tao YX, Abell AN, Liu X, et al . Constitutive activation of G protein-coupled receptors as a result of selective substitution of a conserved leucine residue in transmembrane helix III. Mol Endocrinol. 2000; 14: 1272–82.
- 56 Feng X, Muller T, Mizrachi D, et al . An intracellular loop (IL2) residue confers different basal constitutive activities to the human lutropin receptor and human thyrotropin receptor through structural communication between IL2 and helix 6, via helix 3. Endocrinology. 2008; 149: 1705–17.
- 57 Tao YX, Johnson NB, Segaloff DL. Constitutive and agonist-dependent self-association of the cell surface human lutropin receptor. J Biol Chem. 2004; 279: 5904–14.
- 58 Conn PM, Ulloa-Aguirre A, Ito J, et al . G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev. 2007; 59: 225–50.
Citing Literature
